Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Blood Pressure Imbalances and Circulatory Shock

Blood Pressure Imbalances and Circulatory Shock

Disorders affecting blood volume, vascular tone, or vascular function can disrupt vascular homeostasis, including conditions like hypertension, hemorrhage, and shock.
Blood Pressure: Hypertension and Hypotension
Normal blood pressure is 120/80 mm Hg. Elevated blood pressure is 120-129/under 80 mm Hg. Hypertension, warranting treatment at 130/80 mm Hg, is often asymptomatic and can lead to severe cardiovascular events, aneurysms, peripheral arterial disease, chronic renal disease, or cardiac...

Cardiopulmonary Resuscitation IV: Pharmacological Management

Cardiopulmonary Resuscitation IV: Pharmacological Management

Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...

Cardiomyopathy II: Dilated Cardiomyopathy

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...

Cardiomyopathy V: Interprofessional Care

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...

Heart Failure V: Medical Management

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...

Acute Coronary Syndrome IV: Interprofessional Care

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Exercise training for cardiovascular prevention in patients with cancer.

European heart journal·2026

Same author

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and Cancer Risk: Insights from a Large Propensity-Matched Cohort Study.

Clinical pharmacology and therapeutics·2026

Same author

The Prognostic Significance of Coronary Artery Disease Interventions in Lung Transplant Candidates.

Cardiology·2025

Same author

Universal definition of myocardial infarction: what must we know? What is next?

Heart (British Cardiac Society)·2024

Same author

Cardiovascular toxicities of immune therapies for cancer - a scientific statement of the Heart Failure Association (HFA) of the ESC and the ESC Council of Cardio-Oncology.

European journal of heart failure·2024

Same author

Left Atrial Strain: Clinical Use and Future Applications-A Focused Review Article.

Reviews in cardiovascular medicine·2024

Search research articles

Related Experiment Video

Updated: Jul 13, 2026

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

Cardiogenic shock: treatment.

Zaza Iakobishvili¹, David Hasdai

¹Intensive Cardiac Care Unit, Department of Cardiology, Rabin Medical Center, Beilinson Campus, 39 Jabotinsky Street, Petah Tikva, Israel 49100.

The Medical Clinics of North America

|July 21, 2007

Summary

Treating cardiogenic shock involves medical therapy, revascularization, surgery, and devices. Timely revascularization is the only evidence-based therapy proven to improve survival in acute coronary syndromes.

Area of Science:

Cardiology
Critical Care Medicine

Background:

Cardiogenic shock complicating acute coronary syndromes presents complex treatment challenges.
Current medical therapies lack definitive survival benefits.

Purpose of the Study:

To review and summarize the current treatment strategies for cardiogenic shock.
To highlight evidence-based therapies and emerging options.

Main Methods:

Literature review of medical therapy, percutaneous revascularization, cardiac surgery, and device implantation.
Analysis of evidence for survival benefit in cardiogenic shock treatment.

Main Results:

Medical therapies (inotropic/vasoactive drugs) show limited survival benefit.
Timely revascularization is the sole evidence-based therapy with proven survival benefit.

More Related Videos

The Intra-Aortic Balloon Pump

The Intra-Aortic Balloon Pump

Published on: February 5, 2021

Related Experiment Videos

Last Updated: Jul 13, 2026

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

The Intra-Aortic Balloon Pump

The Intra-Aortic Balloon Pump

Published on: February 5, 2021

Intra-aortic balloon pump counterpulsation remains a key supportive treatment.

Conclusions:

Effective cardiogenic shock management requires a multi-faceted approach.
Timely revascularization is critical for improving survival outcomes.
Further research is needed for novel pharmacologic agents and advanced device therapies.